Skip to main content
AIM ImmunoTech Inc. logo

AIM ImmunoTech Inc. — Investor Relations & Filings

Ticker · AIM ISIN · US42366C3016 US Professional, scientific and technical activities
Open in API
Filings indexed 1,092 across all filing types
Latest filing 2024-11-26 Proxy Solicitation & In…
Country US United States of America
Listing US AIM

About AIM ImmunoTech Inc.

https://aimimmuno.com/

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for various diseases. The company's primary areas of focus include oncology, immune disorders, and viral diseases. Its lead drug candidate is Ampligen® (rintatolimod), a proprietary immuno-modulator with broad-spectrum activity demonstrated in pre-clinical testing. Ampligen® is being evaluated in multiple clinical studies for a range of debilitating and life-threatening conditions.

Recent filings

Filing Released Lang Actions
DFAN14A
Proxy Solicitation & Information Statement
2024-11-26 English
Remuneration Information 2024
Remuneration Information Classification · 95% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or related materials filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes detailed information about the solicitation of proxies for the company's 2024 Annual Meeting of Stockholders, including presentations, voting instructions, and information about board nominees. The text explicitly references the Definitive Proxy Statement and proxy solicitation materials, and urges shareholders to vote. It also includes exhibits related to the proxy solicitation. This type of filing corresponds to Remuneration Information (DEF 14A) filings, which cover proxy statements and executive compensation details. The document is not an Annual Report, Earnings Release, or other financial report, but a proxy solicitation filing. Therefore, the correct classification is DEF 14A with high confidence.
2024-11-25 English
Proxy Solicitation & Information Statement 2024
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or additional materials related to a proxy solicitation for an annual meeting of stockholders. It includes references to the solicitation of proxies, participants in the solicitation, and encourages stockholders to read the definitive proxy statement and related materials. The document also mentions an investor presentation attached as an exhibit, intended for discussions with stockholders in connection with the 2024 Annual Meeting. The presence of the Schedule 14A form and the focus on proxy solicitation and shareholder meeting materials clearly identify this as a Proxy Solicitation & Information Statement filing. The document length (7065 characters) and content confirm it is not merely an announcement but actual proxy materials or related additional materials. Therefore, the correct classification is PSI (Proxy Solicitation & Information Statement).
2024-11-22 English
Regulatory Filings 2024
Regulatory Filings
2024-11-21 English
Director's Dealing 2024
Director's Dealing
2024-11-21 English
Director's Dealing 2024
Director's Dealing
2024-11-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.